<DOC>
	<DOCNO>NCT00094367</DOCNO>
	<brief_summary>This study design evaluate subject take 600 mg abacavir 300 mg lamivudine once-daily single tablet likely adverse event compare subject take 300 mg abacavir 150 mg lamivudine administer separate tablet twice-daily .</brief_summary>
	<brief_title>A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets ( ALOHA Study )</brief_title>
	<detailed_description>A phase IIIB randomize , open-label , multicenter , parallel-arm study evaluate short-term safety tolerability abacavir/lamivudine fixed-dose combination tablet administer once-daily separate abacavir lamivudine tablet administer twice-daily , part three four-drug regimen , antiretroviral naive HIV-1 infected subject .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Have HIV1 infection . Had receive prior HIV treatment 14 day . At least 1000 copy HIV1 RNA . Willing provide sign informed consent . Enrolled investigational drug study . Female subject pregnant breastfeeding . History allergy hypersensitivity abacavir lamivudine . Certain medical condition would make subject ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>1592U89</keyword>
	<keyword>GR109714</keyword>
	<keyword>abacavir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>fixed-dose combination</keyword>
	<keyword>once-daily</keyword>
	<keyword>twice-daily</keyword>
	<keyword>HIV infection</keyword>
	<keyword>naive</keyword>
</DOC>